Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,752.00+1.36%ETH$2,289.72+1.80%GOLD$3,940.20-0.01%OIL$96.76+0.70%
Smart Investors Daily
SID Premium
SY

NASDAQ · SYRE

Spyre Therapeutics, Inc.

Healthcare · Biotechnology

$95.51

Up+$3.76 (+3.94%)

Updated Nov 3, 2026, 11:06 PM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.07B
P/E ratio
-79.77
Dividend yield
0.00%
52-week range
$39.00 – $110.18
Volume
753.08K
Avg. volume
928.45K

Price performance · SYRE

SYRE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

SYRE closed at $95.51 after 21 trading sessions, up 3.01% for the selected period.

Last close
$95.51
Period change
+3.01%
Period low
$78.63
Period high
$99.75
Daily close
View OHLC price history
SYRE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$97.11$98.13$93.82$95.51753.08K
Oct 30, 2026$96.78$98.96$94.68$96.56661.13K
Oct 29, 2026$99.71$100.42$97.95$98.96567.64K
Oct 28, 2026$98.39$100.14$97.55$99.75724.55K
Oct 27, 2026$93.00$99.24$92.37$99.045944.93K
Oct 26, 2026$91.54$94.19$90.35$92.91637.18K
Oct 23, 2026$90.705$91.90$88.69$90.33503.01K
Oct 22, 2026$92.95$94.565$91.27$92.33802.95K
Oct 21, 2026$92.78$95.17$92.315$92.951.15M
Oct 20, 2026$85.12$93.2199$85.075$91.401.71M
Oct 19, 2026$82.29$86.05$80.94$84.721.27M
Oct 16, 2026$80.21$80.52$78.125$79.901.27M
Oct 15, 2026$76.87$80.88$76.87$80.101.15M
Oct 14, 2026$80.13$82.45$77.95$78.631.62M
Oct 13, 2026$85.12$85.32$80.45$80.451.44M
Oct 12, 2026$86.30$86.62$84.21$85.90873.91K
Oct 9, 2026$79.90$86.22$78.7301$85.691.12M
Oct 8, 2026$79.58$80.91$77.05$79.902.33M
Oct 7, 2026$78.91$82.22$78.00$80.852.72M
Oct 6, 2026$92.08$92.08$79.36$80.114.25M
Oct 5, 2026$93.02$95.01$89.49$92.72642.86K

Latest SYRE news

The latest Smart Investors Daily articles mentioning SYRE.

Stock researchCompany · Overview

SYRE research

Overview

Company profile and research snapshot.

Company profile

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.00
Implied upside
—
Analysts
—
SYRE recent ratings
DateFirmRatingTarget
Oct 19, 2026BTIGBuy—
Oct 12, 2026UBSBuy—
Oct 1, 2026JP MorganOverweight—
Oct 1, 2026BTIGBuy—
Sep 9, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview

Spyre Therapeutics has seen its share price move sharply in recent years, so the question now is whether a US$90.33 stock is adequately supported by what sits on its balance sheet. With the market focused on new inflammatory bowel disease treatments, the key issue is how that enthusiasm lines up with Spyre Therapeutics' book value. Over the past 3 years the stock has delivered a very large gain of roughly 7x which raises the question of how far the business has pulled away from its...

Yahoo · Oct 18, 2026

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By